Twitter LinkedIn

GLP-1 Receptor Agonists

Case study clinic: Escalation to injections
Not started

Case study clinic: Escalation to injections

0.5 hours

Interactive case study

Continue to practice your decision-making when intensifying treatment beyond triple therapy. Featuring local commentary from France, Spain and Italy.

An overview of GLP-1 analogues
Not started

An overview of GLP-1 analogues

1 hour

eLearning module

A comprehensive overview of GLP-1 receptor agonists, including mechanism of action, multifactorial effects and how to predict response to their use in type 2 diabetes.

Intensifying T2D treatment with a GLP-1 RA
Not started

Intensifying T2D treatment with a GLP-1 RA

1 hour

eLearning module

A summary of guideline recommendations in the use of GLP-1 analogues, including how to help patients manage gastrointestinal side effects.

Selecting between therapeutics: Advantages and considerations
Not started

Selecting between therapeutics: Advantages and considerations

1 hour

eLearning module

A comprehensive summary of relevant data across GLP-1RAs, SGLT2 inhibitors and DPP-4 inhibitors, complete with guidance on how to select between these.

Once-weekly injectables:  Within-class differences and their relevance in the real world
Not started

Once-weekly injectables: Within-class differences and their relevance in the real world

1 hour

eLearning module

A review of data surrounding once-weekly GLP-1 receptor agonists, including clinical trial data and how these apply to the real world.

Alternatives to injectable GLP-1 RAs: oral formulations, implantable agents and dual agonists
Not started

Alternatives to injectable GLP-1 RAs: oral formulations, implantable agents and dual agonists

1 hour 1 CME Credit

eLearning module

A summary of formulations, mechanisms of action and clinical trial data associated with alternative approaches to GLP-1 agonism. This includes oral semaglutide, implantable exenatide, and dual agonists (e.g. tirzepatide)

Funding information is available at the beginning of each activity. All content has been developed by Liberum IME in conjunction with an independent steering committee; financial supporters have had no influence on the content of this education.

The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries.Physicians interested in converting AMA PRA Category 1 Credit™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMEC®s) should contact the UEMS at mutualrecognition@uems.eu